相关实验视频

Updated: Jul 26, 2025

How to Measure Cortical Folding from MR Images: a Step-by-Step Tutorial to Compute Local Gyrification Index

How to Measure Cortical Folding from MR Images: a Step-by-Step Tutorial to Compute Local Gyrification Index

Published on: January 2, 2012

与阿尔茨海默病相关区域的皮层厚度/体积更高:保护因素还是危险因素?

McKenna E Williams¹, Jeremy A Elman², Tyler R Bell²

¹Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA; Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, CA, USA; Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.

Neurobiology of aging

|June 21, 2023

概括

更高的皮层厚度可能是早期阿尔茨海默病 (AD) 风险的信号. 将厚度与平均扩散度 (MD) 结合起来,有助于识别未来大脑和记忆能力下降的个体.

科学领域:

神经科学是一个神经科学.
老年学是一门学科.
放射学放射学是一门学科.

背景情况:

在早期阿尔茨海默病 (AD) 中,皮层厚度的变化可能会遵循双相模式.
更高的皮层厚度,而不是更低,有时与早期的AD病理有关.
平均扩散率 (MD) 提供了对大脑组织完整性的见解.

研究的目的:

调查从平均扩散度 (MD) 整合AD大脑特征是否可以改善皮质厚度/体积的解释.
评估皮质厚度/体积作为未来AD相关变化的风险因素,当与MD签名相结合时.

主要方法:

对来自越南时代老龄化双胞胎研究 (平均年龄56岁) 的572名认知正常男性进行分析.
皮质厚度/体积和MD签名的基线评估.
长度随访超过12年,以评估大脑和认知结果.

主要成果:

12年后,具有高基线皮质厚度/体积和高MD标志的个体在AD区域的厚度/体积减少,并且具有较差的情节性记忆.
这与具有高厚度/体积但低MD签名的人形成鲜明对比.
两组之间没有观察到年轻成人认知储备的差异.

结论:

这些发现支持了双相模型,其中皮质厚度增加可能会先于认知衰退.
检查皮质MD与皮质厚度一起,对于识别有风险的子组是有价值的.
这种综合方法有助于预测不同的大脑和认知结果.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.皮层厚度皮层厚度平均的扩散性是神经成像是一种神经成像.签名签名签名

更多相关视频

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...